A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
10x Genomics, Inc.
TXG
$5.8B
Mkt Cap
$46.27
-3.72%
10x Genomics, Inc. (TXG) has a 5-year average return on invested capital (ROIC) of -18.4%. This is below average and may indicate limited pricing power.
10x Genomics, Inc. (TXG) has a market capitalization of $5.9B. It is classified as a mid-cap stock.
10x Genomics, Inc. (TXG) does not currently pay a regular dividend.
10x Genomics, Inc. (TXG) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
10x Genomics, Inc. (TXG) reported annual revenue of $643 million in its most recent fiscal year, based on SEC EDGAR filings.
10x Genomics, Inc. (TXG) has a net profit margin of -6.8%. The company is currently unprofitable.
10x Genomics, Inc. (TXG) generated $130 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Item 1. Business. Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 639M | 643M | 611M | 619M | 516M | 490M |
| Net Income | -23M | -44M | -183M | -255M | -166M | -58M |
| EPS | $-0.18 | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
| Free Cash Flow | 122M | 130M | -5.7M | -64M | -165M | -123M |
| ROIC | -11.1% | -5.8% | -25.2% | -33.0% | -20.5% | -7.5% |
| Gross Margin | 69.6% | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% |
| Debt/Equity | 0.00 | 0.11 | 0.12 | 0.13 | 0.12 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -39M | -61M | -195M | -265M | -168M | -52M |
| Operating Margin | -6.1% | -9.5% | -31.9% | -42.9% | -32.5% | -10.7% |
| ROE | -2.8% | -5.8% | -25.2% | -33.0% | -20.5% | -7.5% |
| Shares Outstanding | 128M | 124M | 120M | 117M | 114M | 110M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 71M | 146M | 246M | 299M | 490M | 516M | 619M | 611M | 643M | 639M |
| Gross Margin | 85.1% | 20.1% | 75.2% | 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% | 69.6% |
| R&D | 32M | 48M | 83M | 123M | 212M | 266M | 270M | 265M | 239M | 231M |
| SG&A | 47M | 88M | 131M | 202M | 258M | 298M | 343M | 344M | 316M | 293M |
| EBIT | -18M | -111M | -31M | -534M | -52M | -168M | -265M | -195M | -61M | -39M |
| Op. Margin | -25.8% | -75.7% | -12.4% | -178.7% | -10.7% | -32.5% | -42.9% | -31.9% | -9.5% | -6.1% |
| Net Income | -19M | -112M | -31M | -543M | -58M | -166M | -255M | -183M | -44M | -23M |
| Net Margin | -26.4% | -76.9% | -12.7% | -181.6% | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% | -3.5% |
| Non-Recurring | 0 | -251K | -614K | -29K | -79K | 3.1M | 12M | 3.3M | 12M | 12M |
| Returns on Capital | ||||||||||
| ROIC | N/A | -89.1% | -25.5% | -92.1% | -7.5% | -20.5% | -33.0% | -25.2% | -5.8% | -11.1% |
| ROE | 18.0% | 67.7% | -31.2% | -93.6% | -7.5% | -20.5% | -33.0% | -25.2% | -5.8% | -2.8% |
| ROA | N/A | -181.0% | -8.6% | -70.7% | -6.0% | -16.2% | -25.6% | -19.4% | -4.4% | -2.2% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -11M | -76M | 35M | -218M | -21M | -34M | -15M | 6.7M | 136M | 128M |
| Free Cash Flow | -14M | -83M | -8.1M | -255M | -123M | -165M | -64M | -5.7M | 130M | 122M |
| Owner Earnings | -17M | -83M | 14M | -281M | -138M | -196M | -218M | -170M | -9.3M | -11M |
| CapEx | 3.8M | 6.3M | 43M | 37M | 101M | 132M | 49M | 12M | 5.9M | 5.6M |
| Maint. CapEx | 4.3M | 3.9M | 7.1M | 14M | 21M | 25M | 36M | 36M | 36M | 38M |
| Growth CapEx | 0 | 2.4M | 36M | 23M | 80M | 106M | 13M | 0 | 0 | 0 |
| D&A | 4.3M | 3.9M | 7.1M | 14M | 21M | 25M | 36M | 36M | 36M | 38M |
| CapEx/OCF | N/A | N/A | 123.4% | N/A | N/A | N/A | N/A | 186.0% | 4.4% | 4.4% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.7M | 2.7M | 13M | 49M | 96M | 137M | 167M | 141M | 109M | 101M |
| Debt Repayment | 0 | 704K | 0 | 31M | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | -35M | -394M | -601M | -505M | -335M | -293M | -311M | -439M | -540M |
| Cash & Equiv. | 48M | 65M | 424M | 664M | 587M | 220M | 359M | 344M | 474M | 540M |
| Long-Term Debt | N/A | 25M | 20M | 0 | 0 | 0 | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | -0.13 | 0.07 | 0.09 | 0.10 | 0.12 | 0.13 | 0.12 | 0.11 | 0.00 |
| Interest Coverage | -22.7 | -46.0 | -9.9 | -317.6 | -60.3 | -352.8 | -8040.3 | -277.9 | -101.6 | -101.6 |
| Equity | -113M | -220M | 420M | 739M | 818M | 806M | 741M | 710M | 796M | 814M |
| Total Assets | N/A | 124M | 606M | 929M | 1.0B | 1.0B | 965M | 919M | 1.0B | 1.0B |
| Total Liabilities | N/A | 101M | 186M | 190M | 201M | 223M | 224M | 209M | 245M | 201M |
| Intangibles | N/A | 642K | 22M | 22M | 25M | 23M | 17M | 16M | 62M | 60M |
| Retained Earnings | N/A | -231M | -262M | -805M | -863M | -1.0B | -1.3B | -1.5B | -1.5B | -1.5B |
| Working Capital | N/A | 74M | 418M | 656M | 637M | 504M | 469M | 467M | 531M | 556M |
| Current Assets | N/A | 106M | 481M | 774M | 748M | 635M | 596M | 584M | 684M | 670M |
| Current Liabilities | 118K | 32M | 63M | 118M | 110M | 131M | 127M | 118M | 153M | 114M |
| Per Share Data | ||||||||||
| EPS | -1.62 | -8.40 | -0.32 | -5.37 | -0.53 | -1.46 | -2.18 | -1.52 | -0.35 | -0.18 |
| Owner EPS | -1.44 | -6.20 | 0.15 | -2.78 | -1.26 | -1.72 | -1.86 | -1.41 | -0.07 | -0.09 |
| Book Value | -9.71 | -16.43 | 4.36 | 7.31 | 7.44 | 7.09 | 6.33 | 5.91 | 6.40 | 6.35 |
| Cash Flow/Share | -0.92 | -5.71 | 0.36 | -2.16 | -0.19 | -0.30 | -0.13 | 0.06 | 1.09 | 0.12 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 11.6M | 13.4M | 96.2M | 101.1M | 109.9M | 113.7M | 117.0M | 120.1M | 124.4M | 128.3M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -263.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 15.8 | 48.6 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 20.2 | 20.1 | 19.4 | 4.5 | 9.1 | 2.5 | 2.6 | 7.3 |
| Price/Sales | N/A | N/A | 26.0 | 34.2 | 37.9 | 11.9 | 9.2 | 5.2 | 2.4 | 9.3 |
| FCF Yield | N/A | N/A | -0.1% | -1.7% | -0.8% | -4.6% | -0.9% | -0.3% | 6.3% | 2.1% |
| Market Cap | 0 | N/A | 8.5B | 14.9B | 15.9B | 3.6B | 6.7B | 1.8B | 2.1B | 5.9B |
| Avg. Price | 0.00 | N/A | 58.86 | 101.10 | 169.39 | 53.97 | 48.88 | 26.65 | 12.46 | 46.27 |
| Year-End Price | 0.00 | N/A | 78.15 | 147.03 | 144.55 | 31.68 | 57.55 | 14.59 | 16.49 | 46.27 |
10x Genomics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 41.8x vs a median of 15.8x. The company's 5-year average gross margin is 72.9%. At current prices, the estimated annualized return to fair value is +120.3%.
10x Genomics, Inc. (TXG) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
10x Genomics, Inc. (TXG) reported earnings per share (EPS) of $-0.35 in its most recent fiscal year.
10x Genomics, Inc. (TXG) has a return on equity (ROE) of -5.8%. A negative ROE may indicate losses or negative equity.
10x Genomics, Inc. (TXG) has a 5-year average gross margin of 72.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for 10x Genomics, Inc. (TXG), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
10x Genomics, Inc. (TXG) has a book value per share of $6.40, based on its most recent annual SEC filing.